Picture for Karen Paraschin

Karen Paraschin

Research and Development, Pharmaceuticals, Bayer AG, Wuppertal, Germany

Enabling scalable clinical interpretation of ML-based phenotypes using real world data

Add code
Aug 02, 2022
Figure 1 for Enabling scalable clinical interpretation of ML-based phenotypes using real world data
Figure 2 for Enabling scalable clinical interpretation of ML-based phenotypes using real world data
Figure 3 for Enabling scalable clinical interpretation of ML-based phenotypes using real world data
Figure 4 for Enabling scalable clinical interpretation of ML-based phenotypes using real world data
Viaarxiv icon